wholefoodsmagazine

Silver Spring, MD—There needs to be new regulatory pathway for cannabidiol (CBD) that balances consumers’ desire for access to CBD products with regulatory oversight that can manage risks. That’s the conclusion the U.S. Food and Drug Administration (FDA) has reached after convening an internal working group to explore potential regulatory pathways for CBD products.

FDA said it is prepared to work with Congress to develop a cross-agency strategy for the regulation of CBD products.

FDA also reported that it has denied three citizen petitions that called on the agency to conduct rulemaking to allow the marketing of CBD products as dietary supplements. Petitions had been filed by the Consumer Healthcare Products Association (CHPA), the Council for Responsible Nutrition (CRN), and the Natural Products Association (NPA)

“The use of CBD raises various safety concerns, especially with long-term use,” said FDA’s Janet Woodcock, M.D., Principal Deputy Commissioner – Office of the Commissioner, in a statement. “Studies have shown the potential for harm to the liver, interactions with certain medications and possible harm to the male reproductive system. CBD exposure is also concerning when it comes to certain vulnerable populations such as children and those who are pregnant.”

Dr. Woodcock added that a new regulatory pathway would provide consumers with safeguards and oversight to “manage and minimize risks related to CBD products.” Risk management tools could include:

• clear labels
• prevention of contaminants
• CBD content limits
• measures, such as minimum purchase age, to mitigate the risk of ingestion by children.

The new pathway also could provide access and oversight for certain CBD-containing products for animals, Dr. Woodcock noted.

The problem with FDA’s existing foods and supplement authorities:

“The FDA’s existing foods and dietary supplement authorities provide only limited tools for managing many of the risks associated with CBD products,” Dr. Woodcock said. “Under the law, any substance, including CBD, must meet specific safety standards to be lawfully marketed as a dietary supplement or food additive.”

Outlining concerns identified by the working group, Dr. Woodcock said available evidence (which includes studies related to the drug Epidiolex, published scientific literature, information submitted to a public docket, and studies conducted and commissioned by FDA) does not establish:

• How CBD products could meet safety standards for dietary supplements or food additives, with inadequate evidence to determine how much CBD can be consumed, and for how long, before causing harm.
• How CBD products could meet the safety standard for substances in animal food.

Industry responds to FDA’s CBD decision

FDA’s claim that the agency does not have appropriate authority to regulate the CBD was met with strong reaction from natural products industry leaders.

FDA’s “dereliction of duty on CBD regulation”

“This is an astonishing dereliction of duty, especially compared to the agility and professionalism the agency showed it was capable of during the pandemic,” said Daniel Fabricant, Ph.D., NPA President and CEO, in a statement. “After more than a decade of promises, hearings, data sharing, market proliferation, and states filling the regulatory vacuum, the FDA’s Dietary Supplement Division claims it cannot do what Congress authorized, which is to regulate dietary supplements under the law. But it gets scarier. When you read between the lines of today’s FDA statement, the agency appears to be saying that it would prefer to defy and attack DSHEA and develop different regulatory paths for ingredients at its own discretion. That could include requiring premarket approval, unnecessary testing, or who knows what. That is an especially dangerous precedent not only for CBD, but for the entire natural products industry and ingredients like hemp that clearly fall under the agency’s jurisdiction. We couldn’t be more disappointed and will look for relief with every branch of government and will need the help of our members to right the wrong.”

FDA’s “punt” to Congress a disservice to consumers

“Today, FDA continues its long exercise of kicking the can down the road while ignoring the realities of the current marketplace and offering little to show for its purported four-year review of a dietary supplement CBD regulatory pathway,” said CRN President and CEO Steve Mister, in comments that share CRN’s continued frustration with the agency. “FDA has had ample time to consider scientific evidence and develop a regulatory pathway for CBD within the existing legal framework. Since Congress enacted the 2018 Farm Bill, FDA’s inaction and indecision have frustrated consumer interest in having safe and beneficial CBD products available to them and allowed a ‘gray’ CBD marketplace to emerge without meaningful oversight. The agency’s ‘punt’ to Congress, asking it to intervene after four years, is a further disservice to consumers and responsible industry.

“It seems that no level of safety evidence will be good enough for FDA. During the last four years, FDA has repeatedly disregarded evidence demonstrating safety that is relevant to CBD at the levels commonly used in supplements and continues to rely heavily on safety concerns related to high-dosage Epidiolex to support the agency’s inaction. In its statement today, FDA noted that a new regulatory pathway would benefit consumers by providing clear labels, prevention of contaminants, CBD content limits, and limits on use in certain populations—all this can and should be addressed through the existing dietary supplement NDIN process once FDA creates a legal pathway for CBD in dietary supplements. CRN offered the agency a blueprint for that pathway, and it has been ignored.

Regarding CRN’s citizen petition, Mister stated, “FDA’s response to CRN’s CBD citizen petition does not address why safety is a factor in drug preclusion and FDA’s exercise of its rulemaking authority to create a legal pathway for CBD in dietary supplements. In essence, FDA is saying ‘it is because we say it is’—without support for that view in the statute. As we have continued to point out, nothing is stopping FDA from using its rulemaking authority for CBD, other than FDA itself. Instead, FDA suggests Congress must fix this issue when FDA has had the authority to address it all along.

“Today’s announcement and response to our petition does nothing to make consumers any safer. It is yet another example of the agency shrinking from its critical public health role in hopes that Congress will make those decisions instead. CRN looks forward to continuing its work with congressional lawmakers to develop a legislative solution given the absence of FDA leadership.”

Congress urged to act swiftly to protect access to CBD “The Alliance for Natural Health USA strongly disagrees with the FDA’s decision against a rulemaking process to legally permit CBD oil in dietary supplements,” said Gretchen DuBeau, Executive and Legal Director of ANH-USA, in a statement. “We urge Congress to act swiftly to protect access to CBD for the millions of American consumers who rely on this supplement to support their health.” Additional industry statements will be added when available. Related: FDA Warns Companies for Illegally Selling Food & Bev Products Containing CBD
β-NMN Is Not a Dietary Supplement? CRN Responds
Navigating the Hemp/Phytocannabinoids Space

The post FDA: Existing Regulatory Frameworks for Foods & Supplements Not Appropriate for CBD appeared first on WholeFoods Magazine.

Austin, TX—Herbal sales are on the rise. The American Botanical Council (ABC) reported that annual sales of herbal dietary supplements in the U.S. totaled $12.350 billion in 2021. That’s according to ABC’s 2021 Herb Market Report. That figure represents the highest recorded annual spending on these products in the U.S., ABC shared. The number is up 9.7% from the previous year, and is the second-highest annual sales growth for herbal supplements since at least 2000, according to ABC.

The report (published in Issue 136 of HerbalGram) is based on U.S. retail sales data provided by SPINS and Nutrition Business Journal (NBJ). It was written by Tyler Smith, managing editor of HerbalGram; Haleigh Resetar, corporate communications specialist at SPINS; and Claire Morton, senior industry analyst at NBJ.

Key Findings: ABC’s 2021 Herb Market Report

The 2021 Herb Market Report includes tables of total U.S. herbal supplement sales from 2000 to 2021 and the 40 top-selling herbs in the U.S. mainstream and natural retail channels. As ABC reports, several ingredients that saw growth during 2020 at the start of the COVID-19 pandemic continued to see increased sales in 2021. Looking at some specifics:

• In the mainstream retail channel, sales of herbal supplements containing the Ayurvedic adaptogen ashwagandha had the highest sales growth for the second year in a row. 2021 mainstream sales more than quadrupled from 2020.
• 2021 sales of supplements containing apple cider vinegar (ACV) more than doubled compared to 2020  in both mainstream and natural retail outlets.
• Quercetin supplements had the strongest sales growth in the natural channel in 2021.
• Four herbal ingredients in the natural channel experienced sales decreases of more than 30%:
  • • Elderberry. ABC reported that elderberry supplements were down 41.4% from 2020, yet still ranked fourth in sales in the natural channel in 2021. ABC attributed this to the very strong demand during the first year of the pandemic, which then tapered off in 2021.
    • Echinacea/goldenseal combination products
    • Echinacea (single-herb formulations)
    • Oregano

Consumers focused on self care embrace herbs

“Based on the near-record sales growth of herbal supplements in 2021, it appears that consumers continued to prioritize self-care using herbal dietary supplements during the second year of the pandemic,” said Smith, in the press release. “As pandemic-related stressors became somewhat entrenched in 2021, consumer spending increased for products in categories such as mood support, digestive health, and energy. Perhaps surprisingly, sales decreased for some herbs commonly sold for immune support, but 2021 sales of these ingredients were still largely higher than in 2019. This suggests that consumer spending in some supplement categories may be returning to pre-pandemic levels.”

ABC Founder and Executive Director Mark Blumenthal added: “The annual ABC Herb Market Report is one of the most comprehensive and well-researched publications reflecting the continued consumer demand for health-promoting, plant- and fungi-based natural products. For over 30 years, ABC has informed the public of the almost uninterrupted growth in the public’s interest in and uses of herbs as natural products for a wide variety of health benefits.”

Blumenthal expressed ABC’s deep gratitude to HerbalGram Smith, who has co-authored the annual ABC Herb Market Report since 2014, as well as to SPINS and NBJ for their collaboration.

HerbalGram’s 2021 Herb Market Report is available for free on ABC’s website.

The post ABC 2021 Herb Market Report: Herbal Supplements in the U.S. Topped $12 Billion appeared first on WholeFoods Magazine.

On December 23, 2022, the House passed the Consolidated Appropriations Act of 2023 (H.R.2617), an omnibus spending bill consisting of all 12 fiscal year 2023 appropriations bills. It provides $1.7 trillion in discretionary resources across the fiscal year 2023 appropriations bills.

The government funding package includes emergency supplemental funding to help deal with recent natural disasters and extreme weather events, as well as emergency resources to support Ukraine. What it does not include: provisions establishing a mandatory product listing (MPL) requirement for dietary supplements marketed in the United States.

Industry responds to exclusion of MPL provisions Natural products industry leaders have been divided on the topic of MPL.

The American Herbal Products Association (AHPA) reported that the exclusion of MPL provisions came within weeks of AHPA’s letter to the leadership of the Senate and House of Representatives committees with oversight over the U.S. Food and Drug Administration (FDA). AHP requested that MPL language be excluded from any must-pass appropriations legislation considered during the last weeks of this Congress. AHPA also noted that the exclusion of MPL followed a December 7 floor speech in which Sen. Dick Durbin (D-IL) made his final appeal to his Senate colleagues to include MPL legislation in the omnibus bill.

AHPA shared,”AHPA has been actively engaged with legislative discussions on MPL for years and will continue to represent the diverse perspectives of AHPA’s membership in future discussions. These efforts, among others, are part of AHPA’s continued advocacy for modern dietary supplement regulations that will provide greater consumer access to truthful information and a more equitable and transparent path to market for new dietary ingredients.”

Related: AHPA: Mandatory Product Listing Could Cost Dietary Supplement Industry $20M

Daniel Fabricant, Ph.D., President and CEO of the Natural Products Association (NPA), said, “This is a big win for consumers, for innovation, and for access to the healthy products that millions of Americans rely on and turned to during the height of the pandemic. We expected that industry critics would try to use the lame duck as another backdoor opportunity to jam this through and that’s exactly what happened. But thanks to NPA’s advocacy and the tens of thousands of individuals who took part in our grassroots campaign, that effort was rejected. We are incredibly thankful to our members, our Board of Directors, and our allies in Congress who stood firm against this misguided and unnecessary approach.”

Related: NPA Alerts DHS, HHS & DOJ to Concerns with Dietary Supplement Listing Act of 2022

Commenting on behalf of the Alliance for Natural Health USA, Gretchen DuBeau, Executive and Legal Director, said,”ANH welcomes the news that mandatory product listing will not be included in the omnibus funding bill this year. U.S. consumers appreciate access to a broad range of affordable dietary supplements. They do not want unnecessary additional regulation that will increase costs and decrease access to this overwhelmingly safe option to support their health naturally.”

The Consumer Healthcare Products Association (CHPA) applauded the passage of the omnibus appropriations bill, which it said includes several CHPA-backed measures “Included in this package is the Modernization of Cosmetics Regulation Act,” CHPA shared. “Beauty and personal care products have an excellent safety record, but the key statutory provisions authorizing FDA regulation of these products have not been updated since the enactment of the Federal Food, Drug, and Cosmetic Act of 1938. CHPA has long pushed for the modernization of these regulations and is pleased that FDA will now have the appropriate authority and resources it needs to oversee this sector for decades to come.

“Additionally, the inclusion of the INFORM Consumers Act will protect millions of American consumers from bad actors peddling counterfeit and stolen goods by creating more transparent and accountable marketplaces. CHPA thanks Senators Dick Durbin and Bill Cassidy and Representatives Jan Schakowsky and Gus Bilirakis for their leadership on this critical issue.

Related: Dietary Supplement Listing Act of 2022 Introduced; Industry Divided

Regarding MPL, CHPA said it is supportive of the concept, but “we do not support it as a standalone measure, as FDA requires more tools to remove bad actors and illegal products from the marketplace. CHPA supports a more comprehensive approach to regulatory reform that includes MPL, as well as additional tools FDA needs to stop criminals, such as increased cGMP inspections and Remote Regulatory Assessments. While CHPA appreciates the attention given to dietary supplement reform this year, there is undoubtedly still more work to be done to appropriately balance consumer access with FDA oversight, and CHPA looks forward to working with lawmakers in support of comprehensive dietary supplement reform in the 118th Congress.”

Commenting on its stance on MPL and clarifying its view of what MPL is, the Council for Responsible Nutrition (CRN), stated: “CRN is a longtime supporter of FDA’s calls for a federal dietary supplement listing program as a critical new tool for the agency, retailers, and consumers offering more transparency of the dietary supplement marketplace in the U.S. CRN’s Board of Directors, which drives the association’s policies and legislative strategy, has repeatedly endorsed both the general policy and the specific legislative aspects of a dietary supplement product registry for several years. In 2017, CRN launched the Supplement OWL as a model of a product registry, which is now required for CRN members who market supplements in the U.S., and to which many non-member companies voluntarily submit their labels as well.”

CRN also clarified: “Dietary Supplement Listing Act is not a form of premarket approval. Nothing in the original legislation conferred any ability by FDA to reject a submitted label and in an effort to counter this misinformation campaign, CRN requested and obtained the insertion of language stating, “Nothing in this section shall be construed…to grant the Secretary authority to require the approval of a dietary supplement prior to marketing.” More recently accepted revisions would also add, “A listing is deemed complete once all fields of required information have been completed by the responsible person who represents that the product will be marketed in the United States as a dietary supplement.” Claims that dietary supplement listing is akin to premarket approval of supplements are just false.”

Related: CRN Outlines Stance on Mandatory Product Listing  What’s Next for MLP? AHPA said Sen. Durbin reportedly has vowed to continue to push for MPL legislation in the next Congress, which will convene in January 2023.

The post Mandatory Product Listing for Dietary Supplements Not Included in FY23 U.S. Spending Bill; Industry Reacts appeared first on WholeFoods Magazine.

For the first time in nearly 25 years, the Federal Trade Commission (FTC) Bureau of Consumer Protection has revised its business guidance for health products. According to an announcement from FTC, the new Health Products Compliance Guidance represents a “substantial” update to the 1998 guide Dietary Supplements: An Advertising Guide For Industry.

In the report, which is intended as business guidance only, FTC explains: “Since 1998, the FTC has settled or adjudicated more than 200 cases involving false or misleading advertising claims about the benefits or safety of dietary supplements or other health- related products, including foods, over-the-counter (OTC) drugs, homeopathic products, health equipment, diagnostic tests, and health-related apps. This update draws on the issues raised in those cases to illustrate how the FTC identifies the express and implied claims conveyed in advertising and how the agency evaluates the scientific support for those claims. While most of the examples involve dietary supplement advertising, the same legal principles apply to the marketing of any health-related product.”

FTC’s Health Products Compliance Guidance includes:

• Guidance covering all health-related products (not just dietary supplements).
• 23 new examples to help direct marketers and sellers of health products.
• Updates to FTC guidance documents on endorsements and testimonials and the enforcement policy statement on homeopathic drugs.
• More details on the amount and type of evidence needed to substantiate health-related claims. FTC said this includes its expectations related to high quality randomized, controlled human clinical trials.

Related: Regulatory and Enforcement Update on Notable Action in the Cognition, Adaptogen & Nootropic Space
Are Your Supplements Really Regulated and How?
Claims & Labeling: 5 Takeaways from the Dietary Supplements Regulatory Summit

The post FTC’s New Business Guidance for Marketers & Sellers of Health Products appeared first on WholeFoods Magazine.

Atlanta, GA—Cases of respiratory syncytial (RSV) and the flu have increased in recent weeks, triggering shortages of infants’ and kids’ pain relievers and fever reducers. The Washington Post reports that supplies of pediatric formulations such as liquid acetaminophen and ibuprofen have become scarce as the flu, coronavirus and RSV have swept the nation, prompting a huge demand for the drugs that manufacturers are trying to meet. 

In response, Genexa is working to provide retailers additional supplies of clean pain-relievers. Made with the same ingredients as leading brands, Genexa is a clean-label brand, meaning its products have no artificial fillers, including dyes, artificial sweeteners, and artificial preservatives. Genexa says the lack of artificially derived inactive ingredients is helping the company stay on top of the shortage. 

“We want families to know we are here for them and have clean, effective infants’ and kids’ pain relievers and fever reducers that deliver the same, effective acetaminophen as other brands but without all the artificial inactive ingredients,” said David Johnson, Genexa CEO and Co-Founder. “We started Genexa because we wanted a clean choice for our families—and for all families—it’s just what people deserve. We’re committed to keeping shelves stocked during this time as we continue to provide widespread access to our medicines.”

Demand for Clean Medicine

Shayna Smith, M.D., Pediatrician with Flourish Pediatrics in Sandy Springs, GA, said, “Many of my patients are actively seeking out products without unnecessary artificial ingredients that are not only better suited for their lifestyles, but are thoughtfully made with situations like this in mind. I’m grateful I can recommend products like Genexa’s Infants’ and Kids’ Pain & Fever as effective, and widely available options people can turn too as other branded pain and fever medicines may become increasingly hard to find.”

Genexa offers a range of treatments, including cold and flu, analgesics, digestive, and allergy for infants, kids, and adults. To ensure transparency among ingredients used, the company created an Ex List, a “…published list of unnecessary inactive ingredients the company vows to never use in their medicine, including artificial inactive ingredients like artificial dyes, talc, sorbitol, high fructose corn syrup, propylene glycol, titanium dioxide, and common allergens like gluten and lactose.” 

Related: Keeping Kids Happy & Healthy
GIG Cares Opens Registration for 2023 GF Teen Summit 

. 

The post Genexa Works to Offer Clean Medicine to Families Amid Shortages appeared first on WholeFoods Magazine.

Washington, D.C.—In the latest efforts in the fight to ensure access to dietary supplements, the Natural Products Association (NPA) wrote a letter to New York Governor Kathy Hochul, urging for New York bill S16/A431 to be vetoed. The legislation “relates to establishing restrictions on the sale of over-the-counter diet pills and dietary supplements for weight loss or muscle building; prohibits the sale of over-the-counter diet pills or dietary supplements for weight loss or muscle building to people under 18 unless properly prescribed by a health care provider; exempts certain protein powders, protein drinks and foods.”

NPA calls the bill “a slap in the face to public health and anti-consumer choice.”

NPA said the NY legislation is similar to legislation put forth in California that was vetoed by California Gavin Newsom. Failure to comply with the NY legislation would result in a fine of up to $500 for each infraction, NPA reported, adding that the “flawed legislative analysis provided to senators even went so far as to suggest that certain nutrients, including vitamin D and calcium, are potentially harmful.”

“It’s disingenuous and flat-out wrong to suggest the use of dietary supplements causes eating disorders,” said Daniel Fabricant, Ph.D., NPA President and CEO. “There is not a single data point that reflects these absurd claims. The dietary supplement industry has an extensive history of providing consumers with well-researched, trusted products as evidenced by the 80% of Americans who use at least one dietary supplement as a safe and affordable way to maintain a healthy lifestyle. We are urging Governor Hochul to follow the science and data provided by the FDA and veto this irrational legislation.”

NPA Testifies Against Age-Restriction Bill in NJ

NPA has opposed similar age-restriction legislation in California, Massachusetts, Missouri, Rhode Island, and New Jersey, where efforts are ramping up on NJ legislation Bill A3512. The NJ bill seeks to prohibit sale of certain diet pills and dietary supplements for muscle building to persons under 18 years of age under certain circumstances. Kyle Turk, NPA Vice President of Government Affairs, testified at New Jersey Assembly meetings on A3512 on November 14, 2022 and again on December 15 (hear his testimony at the 2:25:00 mark).

“The truth is, prohibiting the sale of healthy, safe, and legal products to minors will do nothing to promote public health and will do more to undermine it,” Turk testified in November. “One must also consider that this would be the first time in America’s history banning a food product for use by a specific category of people. As written, the bill would ban ingredients found in commonly found foods. For example, lipotropics may sound unnatural to some, but it is located in the healthy and recommended foods we want our children to eat. This includes lean cuts of beef, chicken, turkey, bison, dairy, eggs, milk, and even some chocolate as a treat. Creatine, found in red meat, has a long history of safe use and is the most researched dietary supplement, with more than 1,612 clinical trials currently being conducted, which would be prohibited from sale. Branch Chain Amino Acids and Essential Amino Acids, which also have an extensive history of safe use, would be banned.”

NPA is Engaging its Grassroots Network

NPA is urging the industry to contact their state legislators to warn them of the consequences of age-restriction legislation in NJ and beyond. Access the action center here. 

Evidence that such grassroots efforts can have an impact can be seen in NPA’s efforts to protect access to supplements in California, where Governor Gavin Newsom vetoed Assembly Bill 1341, which called for restricting access to dietary supplements. Read full coverage here.

The post NPA Takes Action Against Bills to Age-Restrict Supplements in NY, NJ appeared first on WholeFoods Magazine.

Washington, D.C.—Organic & Natural Health Association (O&N Health) is gearing up to host its 8th annual conference, taking place from January 17-19, 2023, at The Westin Cape Coral Resort at Marina Village in Cape Coral, FL. O&N Health conference is designed to optimize networking while promoting meaningful discussions on issues impacting the natural products industry and consumers.

The theme of this year’s conference is “Disrupting Dysfunction: Securing Supply Chain Integrity,” and much of the content was developed as a result of O&N Health’s board conference retreat to San Miguel, Mexico, in 2022. Conference sponsors include Mercola, AIDP, and Chr. Hansen.

For an early kickoff to the event, attendees can participate in optional networking events on January 16, including 18 holes of golf, followed by dinner and a “Bogeys, Beers & Bourbon” tasting. On January 17, the opening reception and dinner will support a community Hurricane Ian restoration project.

The conference will also address a range of pressing topics, with keynote presentations by Dan Lifton, CEO of QOL Labs and O&N Health treasurer, and Dan Richard, Vice President of Global Sales and Marketing at NOW Foods. “We have a lot of critical issues to cover, and I predict 2023 will be a big year for Organic & Natural Health and the natural products industry,” said Karen Howard, CEO and Executive Director of O&N Health. “This is our most important gathering of the year.”

Focusing on “The Amazon Factor”

The event will feature a panel of industry experts including Elan Sudberg, CEO of Alkemist Labs, and Chris Burkhart, Senior Vice President of Sales at Nutrasource, discussing “The Amazon Factor” and proposing strategies for improving quality assurance for consumers.

O&N Health was recently honored with WholeFoods Magazine’s 2022 Person of the Year  for being one of the quality activists of Amazon.com during the past several years. O&N Health noted that its efforts, along with initiatives from fellow colleagues and companies in the industry including NOW and Alkemist, have put pressure on the online giant. Howard stresses that uniting the industry on this issue is key to finding solutions with Amazon that everyone can tolerate.

“We need a cohesive industry response to the issues arising from Amazon,” said Howard. “Addressing the ‘Amazon factor’ is a complex issue that requires everyone to be equally vested in a business case that can serve the entire industry, while benefiting consumers and supporting our retailers. I am optimistic that the balanced and scientifically determined actions we have taken will result in true collaboration, which is why this issue is at the top of our agenda at the conference this year.”

More topics at the O&N Health event:

• Regenerative agriculture innovation for the supply chain
• Using blockchain technology to win back consumer trust
• Recruitment and retention strategies in the workplace
• Failings and fixings with 2023 politics
• Adopting ESG (environmental, social, governance) as an investment strategy
• Bringing to light the issues surrounding synthetic biology
• A state of the industry address by Tom Aarts, managing director of Nutrition Business Advisors.

Registration for O&N Health’s conference is open to members; nonmembers and the media may attend by invitation only. Register before December 31 to receive discount pricing and reserve a room at the Westin before December 23 for special block room rates. Learn more at: https://organicandnatural.org.

Related: 2022 Person of the Year: The Amazon.com Quality Activists
2023 Marketing and SEO Trends Your Brand Needs to Succeed
Longevity Science: Optimizing Health, Fitness & Body Composition at Any Age

 

The post O&N Health Conference to Address “The Amazon Factor” & More appeared first on WholeFoods Magazine.